ciccio bellico
BCE o BC fa?
- Registrato
- 26 Febbraio 2015
- Messaggi
- 858
Sulla perdita di efficacia dei vaccini uno studio sulla popolazione svedese, è ancora in revisione critica (non valutato da terzi).
Methods.
The cohort comprised 842,974 pairs (N=1,684,958), including individuals vaccinated with 2 doses and matched unvaccinated individuals.
Cases of symptomatic infection and severe Covid-19 (hospitalization or 30-day mortality after confirmed infection) were collected from 12 January to 4 October 2021.
Findings.
Vaccine effectiveness of BNT162b2 (Pfizer) against infection waned progressively from 92% at day 15-30 to 47% at day 121- 180, and from day 211 and onwards no effectiveness could be detected.
The effectiveness waned slightly slower for mRNA-1273 (Moderna), being estimated to 59% from day 181 and onwards.
In contrast, effectiveness of ChAdOx1 (AstraZeneca) was generally lower and waned faster, with no effectiveness detected from day 121 and onwards, whereas effectiveness from heterologous ChAdOx1- 19 / mRNA was maintained from 121 days and onwards 66%.
For the outcome severe Covid-19, effectiveness waned from 89% at day 15-30 to 42% from day 181 and onwards.
In a sensitivity analysis, individuals >80 years old were excluded. In the remaining cohort, the effectiveness was 80% from day 181 and onwards.
Interpretation.
Vaccine effectiveness against symptomatic Covid-19 infection wanes progressively over time across all subgroups, but at different rate according to type of vaccine, and faster for men and older frail individuals.
The effectiveness against severe illness seems to remain high through 9 months, although not for men, older frail individuals, and individuals with comorbidities.
From 6 months through 9 months after vaccination, the effectiveness against severe disease was a borderline significant 52% in men compared to a robust 73% in women. (*)
This strengthens the evidence-based rationale for administration of a third booster dose.
(*) Secondo gli svedesi i maschietti devono correre a farsi la terza dose.
Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study
Background: Whether vaccine effectiveness against Coronavirus disease 2019 (Covid-19) lasts longer than 6 months is unclear.<br><br>Methods: A retrospective coh
papers.ssrn.com
Methods.
The cohort comprised 842,974 pairs (N=1,684,958), including individuals vaccinated with 2 doses and matched unvaccinated individuals.
Cases of symptomatic infection and severe Covid-19 (hospitalization or 30-day mortality after confirmed infection) were collected from 12 January to 4 October 2021.
Findings.
Vaccine effectiveness of BNT162b2 (Pfizer) against infection waned progressively from 92% at day 15-30 to 47% at day 121- 180, and from day 211 and onwards no effectiveness could be detected.
The effectiveness waned slightly slower for mRNA-1273 (Moderna), being estimated to 59% from day 181 and onwards.
In contrast, effectiveness of ChAdOx1 (AstraZeneca) was generally lower and waned faster, with no effectiveness detected from day 121 and onwards, whereas effectiveness from heterologous ChAdOx1- 19 / mRNA was maintained from 121 days and onwards 66%.
For the outcome severe Covid-19, effectiveness waned from 89% at day 15-30 to 42% from day 181 and onwards.
In a sensitivity analysis, individuals >80 years old were excluded. In the remaining cohort, the effectiveness was 80% from day 181 and onwards.
Interpretation.
Vaccine effectiveness against symptomatic Covid-19 infection wanes progressively over time across all subgroups, but at different rate according to type of vaccine, and faster for men and older frail individuals.
The effectiveness against severe illness seems to remain high through 9 months, although not for men, older frail individuals, and individuals with comorbidities.
From 6 months through 9 months after vaccination, the effectiveness against severe disease was a borderline significant 52% in men compared to a robust 73% in women. (*)
This strengthens the evidence-based rationale for administration of a third booster dose.
(*) Secondo gli svedesi i maschietti devono correre a farsi la terza dose.
Ultima modifica:
..allora ci sei??? ero in pensiero per te 
ed ero preoccupato che non ti avessero seppellito in cantiere
l'ubriaco?
